ZK-283197
ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]
| Clinical data | |
|---|---|
| Other names | BAY 86-5310; SH-T04211C |
| Routes of administration | By mouth[1] |
| Drug class | Estrogen; Selective ERβ agonist |
| Identifiers | |
| CAS Number | |
References
- "ZK 283197 - AdisInsight". adisinsight.springer.com.
- US 14/332,204, Pietras, R. J., & Jung, M. E., "Methods of using estrogen receptor-beta ligands as radiation mitigators"
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.